Applied Therapeutics, Inc. (APLT): Price and Financial Metrics
GET POWR RATINGS... FREE!
APLT Stock Price Chart Interactive Chart >
APLT Price/Volume Stats
| Current price | $0.87 | 52-week high | $22.27 |
| Prev. close | $0.95 | 52-week low | $0.73 |
| Day low | $0.86 | Volume | 401,100 |
| Day high | $0.94 | Avg. volume | 420,513 |
| 50-day MA | $1.46 | Dividend yield | N/A |
| 200-day MA | $6.39 | Market Cap | 22.70M |
Applied Therapeutics, Inc. (APLT) Company Bio
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY
Latest APLT News From Around the Web
Below are the latest news stories about Applied Therapeutics Inc that investors may wish to consider to help them evaluate APLT as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayGood morning, trader! |
Why Applied Therapeutics Stock Is Sliding TodayThe company's lead candidate, AT-007, is going to take a lot longer to reach patients than expected. |
Applied Therapeutics To Hold Filing FDA Application For AT-007 In Rare Metabolic DisorderFollowing discussions with the FDA, Applied Therapeutics Inc (NASDAQ: APLT) has decided to hold on submitting a marketing application for AT-007 for Galactosemia pending additional talks with the agency. Although the Galactosemia program had previously been discussed for Accelerated Approval based on reduction in galactitol, the FDA has now indicated that clinical outcomes data will likely be required for approval. Related: Applied Therapeutics Stock Drops On Delayed NDA Submission For Its Lead |
Applied Therapeutics Provides Regulatory Update on Galactosemia ProgramNEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today provided a regulatory update on the AT-007 Galactosemia program. Following discussions with the FDA at the end of the year, the Company has decided to hold on submitting an NDA for AT-007 for treatment of Galactosemia pending additional d |
Applied Therapeutics Tanks as Drug Candidate for Rare Disease Faces DelaysBy Dhirendra Tripathi |
APLT Price Returns
| 1-mo | -29.27% |
| 3-mo | -65.06% |
| 6-mo | -85.05% |
| 1-year | -95.82% |
| 3-year | -89.47% |
| 5-year | N/A |
| YTD | -90.28% |
| 2021 | -59.34% |
| 2020 | -19.32% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...